Could Evkeeza’s New Peds Approval Result in a PRV for REGN?

Regeneron announced FDA has accepted the Evkeeza (evinacumab) sBLA for the treatment of homozygous familial hypercholesterolemia (HoFH) in children ages 5 to 11 with a PDUFA date of March 30, 2023. Recall, in February 2021, Evkeeza received FDA approval for the treatment of HoFH in patients 12 years of age and older (previous FENIX insight). Below, FENIX wonders if the approval could result in a PRV.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.